Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhLTα-Da plus PF versus PF alone in recurrent or metastatic esophageal cancer
ChiCTR-TRC-11001197Phase 2Recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Sep 2010
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human lymphotoxin-alpha derivative, cisplatin and fluorouracil in esophageal cancer (3 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: progression-free survival and objective response rate. Started Sep 2010; status: recruiting.
02
Drugs
recombinant human lymphotoxin-alpha derivativecisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR-TRC-11001197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001197.